journal article
Open Access
Aug 13, 2018
Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study
Topics
No keywords indexed for this article. Browse by subject →
References
45
[1]
Liang SB, Wang Y, Hu XF, He SS, Yang XL, Liu LZ, et al. Survival and toxicities of IMRT based on the RTOG protocols in patients with nasopharyngeal carcinoma from the endemic regions of China. J Cancer. 2017;8:3718–24.
10.7150/jca.20351
[2]
National Comprehensive Cancer Network. NCCN Guidelines®. 2018.
https://www.nccn.org/professionals/physician_gls/default.aspx#head-and-neck
. Accessed 15 Feb 2018.
[3]
Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2018;16:645–55.
10.1016/s1470-2045(15)70126-9
[4]
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
Ying Sun, Wen-Fei Li, Nian-Yong Chen et al.
The Lancet Oncology
2016
10.1016/s1470-2045(16)30410-7
[5]
Peng H, Chen L, Zhang J, Li WF, Mao YP, Zhang Y, et al. Induction chemotherapy improved long-term outcomes of patients with locoregionally advanced nasopharyngeal carcinoma: a propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiotherapy. J Cancer. 2017;8(3):371–7.
10.7150/jca.16732
[6]
Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:242–9.
10.1200/jco.2008.18.1545
[7]
Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study
Wen-Ze Qiu, Pei-Yu Huang, Jun-Li Shi et al.
Chinese Journal of Cancer
2016
10.1186/s40880-015-0076-9
[8]
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16(4):1310–7.
10.1200/jco.1998.16.4.1310
[9]
Huang PY, Cao KJ, Guo X, Mo HY, Guo L, Xiang YQ, et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2012;48:1038–44.
10.1016/j.oraloncology.2012.04.006
[10]
Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77:1103–24.
10.1007/s00280-016-2976-z
[11]
Toumi N, Ben Kridis W, Mnejja W, Bouzguenda R, Khanfir A, Ghorbel A, et al. TPF induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: long term results of a Tunisian series. Cancer Radiother. 2018;22(3):216–21.
10.1016/j.canrad.2017.10.005
[12]
Li WF, Li YQ, Chen L, Zhang Y, Guo R, Zhang F, et al. Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy. BMC Cancer. 2015;15:810.
10.1186/s12885-015-1768-x
[13]
Zhang B, Hu Y, Xiong RH, Pan YF, Xu QL, Kong XY, et al. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study. Oncotarget. 2017;
https://doi.org/10.18632/oncotarget.13285
.
10.18632/oncotarget.13285
[14]
Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:1350–7.
10.1200/jco.2001.19.5.1350
[15]
International Nasopharynx Cancer Study Group. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (N or = N2, M0) undifferentiated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1996;35:463–9.
[16]
Jin X, Yi J, Zhou Y, Yan H, Han C, Xie C. Comparison of whole-field simultaneous integrated boost VMAT and IMRT in the treatment of nasopharyngeal cancer. Med Dosim. 2013;38:418–23.
10.1016/j.meddos.2013.05.004
[17]
Zhao W, Lei H, Zhu X, Li L, Song Q, Liang X. Investigation of long-term survival outcomes and failure patterns of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. Oncotarget. 2016;
https://doi.org/10.18632/oncotarget.13564
.
10.18632/oncotarget.13564
[18]
Tang C, Wu F, Wang R, Lu H, Li G, Liu M, et al. Comparison between nedaplatin and cisplatin plus docetaxel combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multicenter randomized phase II clinical trial. Am J Cancer Res. 2006;6:2064–75.
[19]
Wu SX, Xie CY, Jin XC, Zhang P. Simultaneous modulated accelerated radiation therapy in the treatment of nasopharyngeal cancer: a local center’s experience. Int J Radiat Oncol Biol Phys. 2006;87:s40–6.
10.1016/j.ijrobp.2005.12.041
[20]
Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2006;22:4604–12.
10.1200/jco.2004.10.074
[21]
OuYang PY, Xie C, Mao YP, Zhang Y, Liang XX, Su Z, et al. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol. 2013;24:2136–46.
10.1093/annonc/mdt146
[22]
Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730–8.
10.1200/jco.2005.16.790
[23]
Lin S, Lu JJ, Han L, Chen Q, Pan J. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer. 2010;10:39.
10.1186/1471-2407-10-39
[24]
Tan T, Lim WT, Fong KW, Cheah SL, Soong YL, Ang MK, et al. Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;91:952–60.
10.1016/j.ijrobp.2015.01.002
[25]
Su SF, Han F, Zhao C, Huang Y, Chen CY, Xiao WW, et al. Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. Chin J Cancer. 2011;30:565–73.
10.5732/cjc.010.10547
[26]
Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27:3684–90.
10.1200/jco.2008.19.9109
[27]
Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012;104:286–93.
10.1016/j.radonc.2012.08.013
[28]
Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110:398–403.
10.1016/j.radonc.2013.10.020
[29]
Chen C, Chen T, Huang C, Wang J, Fei Z. Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy. Medicine. 2017;
https://doi.org/10.1097/MD.0000000000008434
.
10.1097/md.0000000000008434
[30]
Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol. 2005;23:1118–24.
10.1200/jco.2005.12.081
[31]
Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 trials. Eur J Cancer. 2011;47:656–66.
10.1016/j.ejca.2010.10.026
[32]
Lin J-C, Liang W-M, Jan J-S, Jiang R-S, Lin AC. Another way to estimate outcome of advanced nasopharyngeal carcinoma-is concurrent chemoradiotherapy adequate? Int J Radiat Oncol. 2004;
https://doi.org/10.1016/j.ijrobp.2004.03.002
.
10.1016/j.ijrobp.2004.03.002
[33]
Wu LR, Jiang XS, Song X, Yu HL, Fan YX, Wang FJ, et al. Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis. Oncotarget. 2017;
https://doi.org/10.18632/oncotarget.20389
.
10.18632/oncotarget.20389
[34]
Golden DW, Rudra S, Witt ME, Nwizu T, Cohen EE, Blair E, et al. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013;49:277–82.
10.1016/j.oraloncology.2012.10.003
[35]
Frikha M, Auperin A, Tao Y, Elloumi F, Toumi N, Blanchard P, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). Ann Oncol. 2018;29(3):731–6.
10.1093/annonc/mdx770
[36]
Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki AG, Karayannopoulou G, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol. 2012;23:427–35.
10.1093/annonc/mdr116
[37]
Al-Amro A, Al-Rajhi N, Khafaga Y, Memon M, Al-Hebshi A, El-Enbabi A, et al. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2005;62:508–13.
10.1016/j.ijrobp.2004.09.050
[38]
Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, et al. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2005;63:717–24.
10.1016/j.ijrobp.2005.03.001
[39]
Oh JL, Vokes EE, Kies MS, Mittal BB, Witt ME, Weichselbaum RR, Haraf DJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 2003;14:564–9.
10.1093/annonc/mdg163
[40]
Kwong DL, Pow EH, Sham JS, McMillan AS, Leung LH, Leung WK, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer. 2004;101(7):1584–93.
10.1002/cncr.20552
[41]
Laskar S, Bahl G, Muckaden M, Pai SK, Gupta T, Banavali S, et al. Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:728–36.
10.1016/j.ijrobp.2008.01.032
[42]
How Does Intensity-Modulated Radiotherapy Versus Conventional Two-Dimensional Radiotherapy Influence the Treatment Results in Nasopharyngeal Carcinoma Patients?
Shu-Zhen Lai, Wen-Fei Li, Lei Chen et al.
International Journal of Radiation Oncology*Biolog...
2011
10.1016/j.ijrobp.2010.03.024
[43]
Xue F, Hu C, He X. Induction chemotherapy followed by intensity-modulated radiotherapy with reduced gross tumor volume delineation for stage T3-4 nasopharyngeal carcinoma. Oncotargets Ther. 2017;10:3329–36.
10.2147/ott.s140420
[44]
Cheng SH, Jian JJ, Tsai SY, Yen KL, Chu NM, et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys. 2000;48:1323–30.
10.1016/s0360-3016(00)00779-3
[45]
Ke LR, Xia WX, Qiu WZ, Huang XJ, Yang J, Yu YH, et al. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial. BMC Cancer. 2017;17:134.
10.1186/s12885-017-3080-4
Metrics
21
Citations
45
References
Details
- Published
- Aug 13, 2018
- Vol/Issue
- 13(1)
- License
- View
Authors
Funding
National Natural Science Foundation of China
Award: 11675122
Natural Science Foundation of Zhejiang Province
Award: LY16H160046 and Y17H160051
Cite This Article
Linger Liu, Zhenghua Fei, Mengfeng Chen, et al. (2018). Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study. Radiation Oncology, 13(1). https://doi.org/10.1186/s13014-018-1092-0
Related
You May Also Like
Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer
Rolf F Barth, MGraca H Vicente · 2012
428 citations
Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review
Lukas Käsmann, Alexander Dietrich · 2020
203 citations
Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years
Alan J Katz, Michael Santoro · 2013
170 citations
Reliability of the Spinal Instability Neoplastic Score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases
Charles G Fisher, Rowan Schouten · 2014
156 citations
A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation
Sotiris Prokopiou, Eduardo G. Moros · 2015
117 citations